1. Treatment outcomes of patients with Atopic Dermatitis (AD) treated with dupilumab through the Early Access to Medicines Scheme (EAMS) in the UK
- Author
-
O’Kane, D., Davis, L., Ardern-Jones, M., Laws, P., Shaw, L., Cork, M., Velangi, S., Cooper, H.L., Hudson, R., Smith, A.B., and Rout, R.
- Subjects
Adult ,Adolescent ,Injections, Subcutaneous ,Eczema ,Antibodies, Monoclonal, Humanized ,Severity of Illness Index ,Health Services Accessibility ,United Kingdom ,Dermatitis, Atopic ,Treatment Outcome ,Double-Blind Method ,Clinical Paper ,Humans ,Child ,Retrospective Studies - Abstract
BACKGROUND\ud \ud Dupilumab, a monoclonal antibody against interleukin (IL)-4 receptor alpha that inhibits IL-4/IL-13 signalling is indicated in dermatology for the treatment of moderate-to-severe atopic dermatitis (AD) in adult and adolescent patients 12 years and older and severe AD in children 6-11 years, who are candidates for systemic therapy. Dupilumab received Early Access to Medicines Scheme (EAMS) approval for adults in March 2017.\ud \ud OBJECTIVES\ud \ud The purpose of this study was to assess the efficacy outcomes of treatment with dupilumab in EAMS.\ud \ud METHODS\ud \ud A retrospective analysis of adult patients enrolled in the dupilumab EAMS in the UK. Scores were assessed at baseline and follow up, including the Eczema Area and Severity Index (EASI), Investigator’s Global Assessment Score (IGA) and Dermatology Life Quality Index (DLQI).\ud \ud RESULTS\ud \ud Data were available for 57 adult patients treated with dupilumab for at least 12 weeks; 73.6% of patients had\ud received prior treatment with 3 or 4 immunosuppressants. Baseline scores for the EASI and DLQI were 27.93 (standard \ud deviation, SD 13.09) and 18.26 (SD 6.18) respectively. AD \ud severity scores showed statistically significant improvement at week 16+4 weeks (p
- Published
- 2021